Blog
RSS FeedPosted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
Posted by Michael Wonder on 07 Nov 2022
US Supreme Court to hear Amgen bid to revive cholesterol drug patents
4 November 2022 - The US Supreme Court on Friday agreed to hear Amgen's bid to revive patents on its ...
Posted by Michael Wonder on 03 Aug 2022
AbbVie wins appeal in antitrust case over Humira 'patent thicket'
3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...
Posted by Michael Wonder on 02 Aug 2022
Characteristics of key patents covering recent FDA approved drugs
1 August 2022 - New drugs are protected by patents that block generic competition and allow manufacturers to charge high prices. ...
Posted by Michael Wonder on 20 Jun 2022
EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines
17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...
Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
Posted by Michael Wonder on 13 Jun 2022
IP waiver for COVID vaccines misses the mark in vaccinating the world
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...
Posted by Michael Wonder on 09 Jun 2022
U.S. Senators ask regulators to clear drug patent 'thickets'
9 June 2022 - Letter asks U.S. Patent and Trademark Office to crack down on "highly similar" patents for single ...
Posted by Michael Wonder on 30 May 2022
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
27 May 2022 - ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative ...
Posted by Michael Wonder on 17 May 2022
Understanding ‘evergreening’: making minor modifications of existing medications to extend protections
17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...
Posted by Michael Wonder on 16 May 2022
Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia
17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...
Posted by Michael Wonder on 24 Mar 2022
Leaked TRIPS proposal misguided about improving global COVID-19 vaccination rates
24 March 2022 - The leaked proposal on the waiver on intellectual property rights for COVID-19 vaccines is misguided and ...
Posted by Michael Wonder on 12 Mar 2022
Catalyst Pharmaceuticals and KYE Pharmaceuticals announce a second favourable Canadian Federal Court ruling setting aside approval of Ruzurgi
11 March 2022 - Catalyst Pharmaceuticals and KYE Pharmaceuticals today announced receipt of a favourable decision from the Federal Court of ...
Posted by Michael Wonder on 25 Feb 2022
Updating the Bayh-Dole Act; march-in rights and transparency
24 February 2022 - The Patent and Trademark Law Amendments Act (Bayh-Dole Act [35 USC §200-212]) was enacted in 1980 and ...
Posted by Michael Wonder on 15 Feb 2022
MTAA welcomes patent box legislation
11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...